Research Advancements of Antibody-Drug Conjugates in Breast Cancer at 2024 ASCO Annual Meeting

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, the United States, from May 31 to June 4 in 2024. In recent years, antibody-drug conjugates (ADCs) have become one of the most popular targeted therapies because of their high specificity, efficacy, and low tox...

Full description

Saved in:
Bibliographic Details
Published inZhongliu fangzhi yanjiu Vol. 52; no. 3; pp. 185 - 192
Main Authors Ye, Hunan, Shen, Yulan, Li, Jiaying, Zhou, Huanhuan, Zhang, Fanrong, Wang, Xiaojia
Format Journal Article
LanguageChinese
English
Published Tianjin China Anti-Cancer Association 2025
Magazine House of Cancer Research on Prevention and Treatment
Subjects
2024
Antibodies
antibody-drug conjugates
asco
Breast cancer
Cancer therapies
Conjugates
Toxicity
Online AccessGet full text

Cover

More Information
Summary:The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, the United States, from May 31 to June 4 in 2024. In recent years, antibody-drug conjugates (ADCs) have become one of the most popular targeted therapies because of their high specificity, efficacy, and low toxicity, making them a focal point in this ASCO meeting. Currently, over 100 ADCs are under investigation, demonstrating the considerable development potential of ADCs in the field of targeted cancer therapy. The aforementioned conference reported several recent research advancements regarding ADCs for the treatment of breast cancer (BC). This review summarizes the latest progress of ADCs in BC treatment discussed at the conference.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1000-8578
DOI:10.3971/j.issn.1000-8578.2025.24.0999